Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 spike S2-specific neutralizing antibodies

31 May 2023

Abstract excerpt

Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and authorized for emergency use to control the pandemic. Most COVID-19 therapeutic NAbs prevent the S1 subunit of the SARS-CoV-2 spike (S) protein from binding to the human host receptor. However, the emergence of SARS-CoV-2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37254830
DOI: 10.1080/22221751.2023.2220582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 spike S2-specific neutralizing antibodiesPMID 37254830Read ↗

Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance.Semantic proximity Read ↗

Current Status and Perspectives of Therapeutic Antibodies Targeting the Spike Protein S2 Subunit against SARS-CoV-2Semantic proximity Read ↗

Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane FusionSemantic proximity Read ↗

Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies.Semantic proximity Read ↗

The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 PandemicSemantic proximity Read ↗

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.Semantic proximity Read ↗

Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.Semantic proximity Read ↗

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe diseaseSemantic proximity Read ↗

Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patientsSemantic proximity Read ↗

Neutralizing antibodies targeting SARS-CoV-2 spike proteinSemantic proximity Read ↗

Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2Semantic proximity Read ↗

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.